MedTrace Logo

Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes

NCT01908530 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2019-11-20

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety and efficacy of the Imperial College Microprobe Array Continuous Glucose Sensor in healthy volunteers and in subjects with type 1 diabetes.

Conditions

Interventions

DEVICE

Microprobe glucose sensor

Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Desmond Johnston, PhD, FRCP · Professor of Diabetes & Endocrinology - Imperial College London

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-06-30
Completion
2018-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01908530 on ClinicalTrials.gov